Clinical investigator site applications are now being accepted for acute canine pancreatitis trial
Orlando, Florida, Jan 19, 2020 – Ishihara Sangyo Kaisha, Ltd. and its U.S. subsidiary ISK Animal Health, LLC (collectively, “ISK”), in partnership with AlcheraBio LLC, announce the launch of a US clinical trial for the first treatment of acute canine pancreatitis (ACP) that addresses the unique cascade of inflammatory response in ACP. Starting today, ISK and AlcheraBio will begin accepting clinic requests to apply as clinical investigator sites.
“This will be a very exciting clinical trial, and we are pleased ISK selected us as their partner to conduct this study. Our team understands the need to recruit qualified clinics to participate in this clinical trial, and we will start recruiting clinics in the next few weeks,” states Stephen Bienhoff, DVM, MBA, PhD, Chief Science Officer at AlcheraBio.
AlcheraBio will be evaluating potential clinical investigator sites to participate in the trial during the next few weeks. Ideal sites will have the following criteria:
Currently diagnoses a minimum of 6-8 acute pancreatitis cases per year.
Previous experience as a clinical investigator site or a commitment to training to become a clinical investigator site.
Capable of accommodating cases for 48 hours in the hospital during the critical evaluation and treatment period.
Participating clinical investigator sites will receive the following benefits:
Covered testing and treatment for canine acute pancreatitis for their clients in study.
Ability to continue to provide standard of care for their canine acute pancreatitis cases, in addition to the investigative product.
Investigator compensation for each evaluable case and training honorarium and clinic incentives.
"Canine pancreatitis is a deadly disease that affects dogs of all breeds currently treated only by symptomatic therapy,” explains Dr. Jörg M. Steiner, med.vet., Dr.med.vet., PhD, DACVIM-SAIM, DECVIM-CA, AGAF. “Due to the inflammatory nature of ACP, this is a game changing trial with treatments targeting the LFA-1 pathway.”
Clinics that wish to apply for consideration as a clinical investigator site can contact AlcheraBio at www.alcherabio.com/pancreatitis-study.
About Ishihara Sangyo Kaisha, Ltd. Ishihara Sangyo Kaisha, LTD. is a chemical innovation company based in Japan and listed on the Tokyo stock exchange market that develops a wide range of products in the areas of Agrochemical, Environmental Products, Functional Materials, Health Care Products, and Titanium Dioxide Products. For more information on Ishihara Sangyo Kaisha, visit https://www.iskweb.co.jp/eng/.
About ISK Animal Health, LLC
ISK Animal Health, LLC is Ishihara Sangyo Kaisha’s U.S. subsidiary responsible for the veterinary drug business in the Americas. For more information on ISK Animal Health, visit www.iskanimalhealth.com.
AlcheraBio improves the lives of animals by focusing on new and innovative approaches to conducting veterinary clinical studies while contributing to ground-breaking and life-changing therapies in animal health. As a veterinary Contract Research Organization (CRO) and animal health consultancy group, we are fully committed to advancing animal health and veterinary medicine. We look forward to opportunities where we can support the mission of making the lives of animals better through superior science and research. AlcheraBio is part of Argenta, a full-service R&D and manufacturing company dedicated to providing solutions for the animal health industry.
Forward-Looking Statements Disclaimer Content in this release may contain forward-looking statements with respect to future results, performance and achievements that are subject to risk and uncertainties and reflect management's views and assumptions formed by available information. All statements other than statements of historical fact are statements that could be considered forward-looking statements. When used in this document, words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project" or "should" and similar expressions, as they relate to ISK, are intended to identify forward-looking statements.
Many factors could cause the actual results, performance or achievements of ISK to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, changes in general economic and business conditions, changes in currency exchange rates and interest rates, failure to obtain required governmental and regulatory approvals, introduction of competing products by other companies, lack of acceptance of new products or services by ISK’s targeted customers, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, both referenced and not referenced in this release.